8-K: Relay Therapeutics Reports Strong 2025, Eyes Key 2026 Milestones

Relay Therapeutics announced improved 2025 financial results, extended cash runway into 2029, and outlined critical clinical data readouts for its zovegalisib program in 2026.

Summary

• Relay Therapeutics reported a net loss of $54.9 million for Q4 2025, a reduction from $76.0 million in Q4 2024, and a full-year net loss of $276.5 million for 2025, down from $337.7 million in 2024.
• Revenue for Q4 2025 was $7.0 million, up from $0 in Q4 2024, and full-year 2025 revenue increased to $15.4 million from $10.0 million in 2024.
• Cash, cash equivalents, and investments totaled approximately $555 million as of December 31, 2025, with a projected cash runway extending into 2029.
• Research and development expenses decreased to $55.4 million in Q4 2025 from $68.1 million in Q4 2024, and general and administrative expenses also saw a reduction.
• The company anticipates presenting initial Phase 1/2 data for zovegalisib + fulvestrant in breast cancer at ESMO TAT on March 16, 2026.
• Initial clinical data from the Phase 1 ReInspire trial in PIK3CA-driven vascular anomalies is expected in the first half of 2026, with the pediatric cohort opening ahead of schedule.
• Further updates on breast cancer triplet data and frontline Phase 3 development plans are expected in 2026.
• Zovegalisib recently received Breakthrough Therapy designation from the FDA.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by improved financial metrics, an extended cash runway, and significant clinical progress including a Breakthrough Therapy designation and upcoming data readouts for a key asset.

Positives

• Net loss significantly reduced for both the fourth quarter and full year 2025 compared to 2024, indicating improved financial efficiency.
• Revenue increased substantially in Q4 2025 to $7.0 million from $0 in Q4 2024, and full-year revenue grew by 54% to $15.4 million.
• Operating expenses, including R&D and G&A, decreased due to strategic streamlining and reduced costs on certain programs.
• Cash, cash equivalents, and investments of approximately $555 million provide a strong financial position, extending the cash runway into 2029.
• Zovegalisib received Breakthrough Therapy designation from the FDA, highlighting its potential to address unmet medical needs.
• Promising interim Phase 1/2 ReDiscover trial data for zovegalisib in breast cancer showed a median PFS of 10.3 months and an ORR of 39% (47% for 2L patients), with a manageable tolerability profile.
• The pediatric cohort for the ReInspire trial in vascular anomalies opened ahead of schedule due to faster-than-expected enrollment, indicating strong interest and progress.

Negatives

• Cash, cash equivalents, and investments decreased from $781.3 million at the end of 2024 to $554.5 million at the end of 2025, reflecting ongoing operational burn.
• Despite reductions, the company continues to operate at a significant net loss, which is typical for a clinical-stage biotech but still represents a draw on capital.

Risks

• The impact of global economic uncertainty, geopolitical instability, and public health epidemics on operations and clinical trials.
• Potential delays or pauses in current or planned clinical trials or the development of drug candidates.
• The risk that preliminary or interim results from preclinical or clinical trials may not be predictive of future or final results.
• Challenges in successfully demonstrating the safety and efficacy of drug candidates in later-stage trials.
• Uncertainty regarding the timing and outcome of interactions with regulatory authorities and potential approvals.
• Difficulties in obtaining, maintaining, and protecting intellectual property rights for drug candidates.

Future Outlook

Relay Therapeutics anticipates a pivotal 2026 with multiple clinical milestones for its zovegalisib program, including presenting initial Phase 1/2 breast cancer data at ESMO TAT in March, reporting initial data in PIK3CA-driven vascular anomalies in the first half of 2026, and providing updates on breast cancer triplet data and frontline Phase 3 development plans later in the year. The company expects its current cash, cash equivalents, and investments to fund operations into 2029.

Management Comments

• "Our focus on disciplined execution to date has strengthened the foundation of Relay, aligning our organization to support long-term success. In 2026, Relay is entering a pivotal period defined by multiple upcoming clinical milestones across our zovegalisib program, which recently received Breakthrough Therapy designation from the FDA."
• "We anticipate presenting Phase 1/2 breast cancer data at the upcoming ESMO TAT Congress, reporting initial data in PIK3CA-driven vascular anomalies, and providing updates on our breast cancer triplet data and frontline Phase 3 development plans. These milestones position us to deliver meaningful updates in areas with significant unmet need for patients, while continuing to build momentum toward potential commercialization."

Industry Context

StockSavvy.ai notes that Relay Therapeutics' focus on allosteric, pan-mutant, and isoform-selective PI3K inhibition with zovegalisib represents a differentiated approach in the competitive oncology and rare genetic disease landscape. The Breakthrough Therapy designation for zovegalisib underscores the significant unmet need in PI3K-driven conditions and positions Relay as a potential leader in precision medicine for these patient populations. The ongoing development of PI3K inhibitors faces challenges with toxicity and selectivity, and Relay's Dynamo platform aims to overcome these limitations, potentially setting a new standard for therapeutic index in this class.

Comparison to Industry Standards

• The median Progression-Free Survival (PFS) of 10.3 months for all patients and 11.4 months for second-line (2L) patients in the Phase 1/2 ReDiscover trial for HR+/HER2-, PI3K-mutated metastatic breast cancer compares favorably to historical data for other PI3K inhibitors in similar patient populations, which have often struggled with tolerability and efficacy in heavily pre-treated settings.
• The Objective Response Rate (ORR) of 39% for all patients with measurable disease and 47% for 2L patients is competitive, especially considering the prior CDK4/6 inhibitor treatment, which can limit subsequent treatment efficacy.
• The reported tolerability profile, described as mostly low-grade, manageable, and reversible adverse events, suggests a potential advantage over earlier generation PI3K inhibitors that faced dose-limiting toxicities due to off-target effects.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to positive clinical developments, Breakthrough Therapy designation, extended cash runway, and improved financial performance.
• Patients: Zovegalisib's progress, especially with Breakthrough Therapy designation, offers hope for new, potentially life-changing therapies for patients with PI3K-mutated breast cancer and vascular anomalies, addressing significant unmet medical needs.
• Employees: Strategic streamlining in 2024 and 2025 led to reduced employee costs, indicating past organizational adjustments, but current focus on execution suggests stability for remaining staff.
• Regulatory Authorities: Continued interaction and progress with the FDA, particularly with the Breakthrough Therapy designation, highlights the company's commitment to regulatory compliance and accelerated development pathways.

Next Steps

• Present initial Phase 1/2 ReDiscover trial data of zovegalisib + fulvestrant at ESMO TAT Congress on March 16, 2026.
• Disclose initial clinical data from the Phase 1 ReInspire trial in PIK3CA-driven vascular anomalies in the first half of 2026.
• Announce breast cancer triplet clinical data and frontline Phase 3 study design plan in 2026.
• Continue execution of the Phase 3 ReDiscover-2 trial of zovegalisib + fulvestrant in PI3K-mutated, CDK4/6 pre-treated, HR+/HER2advanced breast cancer.
• Continue execution of Phase 1 ReInspire trial of zovegalisib in PIK3CA-driven vascular anomalies.

Key Dates

Recommendation

The filing presents a compelling case for a 'buy' recommendation. Relay Therapeutics has demonstrated significant financial improvements, including reduced net losses and increased revenue, while extending its cash runway into 2029, providing substantial operational stability. Critically, the lead asset, zovegalisib, has received Breakthrough Therapy designation from the FDA, a strong indicator of its potential and the urgency of the unmet medical need it addresses. Promising interim clinical data in breast cancer, coupled with multiple anticipated data readouts in 2026 for both breast cancer and vascular anomalies, suggest strong clinical momentum. These factors, combined with a differentiated scientific approach, position the company for potential long-term growth and value creation.

Keywords

Relay Therapeutics, RLAY, zovegalisib, PI3K inhibitor, breast cancer, vascular anomalies, clinical trials, financial results, biotechnology, precision medicine, oncology, genetic disease, Breakthrough Therapy